Design Therapeutics (DSGN)Director sold ~$1.14M
Arsani William, Director at Design Therapeutics, sold ~$1.14M of Design Therapeutics shares.
- ~$1.14M
- Approx. value · 218K sh @ $5.25
- 1M
- Holds after · shares reported
- Traded
- Aug 13, 2025
- Filed
- Aug 14, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Aug 13, 2025 · this disclosureInsiderDirector sold ~$1.14M of DSGN shares in the open market
What came next
- Aug 13, 2025InsiderDirector sold ~$1.81M of DSGN shares in the open market
- Sep 9, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 9, 2025, Arsani William, M.D., tendered his resignation as a member of the board of directors (the “Board”) of Design Therapeutics, Inc. (the “Company”), effective September 9, 2025 (the “Effective Date”), which was not the result of any disagreement with the Company on any matter related to its operations, policies or practices.”
- Nov 5, 2025Company filing · Form 8-K · ResultsReported its results
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Design Therapeutics
For Design Therapeutics, OQRO holds 2 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DSGN page.
Other recent filings by Arsani William, Director
The full history of Arsani William, Director is on the profile page.
How this filing works
Other disclosures at Design Therapeutics
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRMay 15, 2026
- SEC Form 13F-HRFeb 13, 2026
- SEC Form 4Aug 14, 2025
- SEC Form 13F-HRFeb 18, 2025
Everything OQRO holds on this company is on its DSGN page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data